Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: Boehringer Ingelheim's faldaprevir granted accelerated assessment from European Medicines Agency


Guru

Status: Offline
Posts: 5627
Date:
Boehringer Ingelheim's faldaprevir granted accelerated assessment from European Medicines Agency
Permalink  
 


Nov 26th, Ingelheim, Germany - The application for European marketing authorisation of faldaprevir a potent second generation oral protease inhibitor, has been fully validated and granted accelerated assessment by the European Medicines Agency. Boehringer Ingelheim is seeking marketing approval of faldaprevir in combination with pegylated interferon and ribavirin for the treatment of a broad range of patients with genotype-1 hepatitis C, including difficult-to-cure populations such as those with HIV co-infection or advanced liver disease.

Full article...

http://hepatitiscnewdrugs.blogspot.co.uk/2013/11/hepatitis-c-boehringer-ingelheims.html



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.